Overview

Tislelizumab Neo-adjuvant Treatment for Resectable RHCC

Status:
Recruiting

Trial end date:
2022-06-01

Target enrollment:

Participant gender:

Summary

This single-arm phase II clinical trial aimed to explore the efficacy and safety of Tislelizumab as neoadjuvant treatment for resectable RHCC patients

Phase:

Phase 2

Details

Lead Sponsor:

Sun Yat-sen University